Verizon Business has been awarded a contract to provide AstraZeneca with a flexible, secure network to support the pharmaceutical company`s current and future communications requirements in South Africa and internationally.
Verizon will provide a private IP network that will enable AstraZeneca to link its South African operations and add international connectivity as required.
Because the network is managed by Verizon Business, AstraZeneca can focus on its core operations without worrying about network provisioning. The managed network services, based on MultiProtocol Label Switching (MPLS) technology, are backed by a full quality of service agreement.
According to Derick Botha at AstraZeneca, one of the world`s leading pharmaceutical companies, the organisation chose to partner with Verizon Business SA due to its global reach and ability to leverage international solutions effectively for a local market: "We needed to ensure our chosen communications partner could not only correctly service and support our branches nationally, but that they were well positioned to deliver international services when needed. Verizon Business certainly demonstrated these capabilities during the tender process. We are proud to be associated with such a strong brand and proven global expertise."
Angela Gahagan, country manager at Verizon Business SA, says: "Businesses today depend on digital networks for the exchange of critical information to staff, partners, branch offices, suppliers and customers. Control over how this information is transferred and protected is imperative to the efficient functioning of organisations. We have recently strengthened our international service offering with additional capacity in our network. This, combined with our adherence to global best practices and our ability to deliver full communications offerings to both local and international companies, is what made our tender to AstraZeneca so strong."
AstraZeneca South Africa is the largest investor in clinical research programmes in the country with more than 60 trials. The company takes part in pivotal research studies that ensure that high quality new products are brought to the market. This in turn gives the South African medical profession the opportunity to be at the forefront of new discoveries, as well as the confidence to prescribe products knowing that they have been researched in South Africa.
Share